Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.
Alex Wasyl, CEO Nexien BioPharma

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Alex Wasyl, CEO Nexien BioPharma

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.




Related Articles

CEO Interview

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Newsmakers

American Premium Water Corp. (OTC: HIPH) CEO Provides Update to Shareholders on Q1 and Outlook for Remainder of 2019

May 10, 2019 admin Newsmakers Comments Off on American Premium Water Corp. (OTC: HIPH) CEO Provides Update to Shareholders on Q1 and Outlook for Remainder of 2019

PLAYA VISTA, May 09, 2019 – American Premium Water Corporation (OTC: HIPH) CEO Ryan Fishoff provides an update to shareholders on the Company’s progress in the 1 quarter and outlook for the rest of the year. […]

Healthcare

CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution

June 17, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution

VANCOUVER, Washington, June 14, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today that it […]